Avian Influenza Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (H5 Strain,H7 Strain,H9 Strain), By Application (Chicken,Duck & Goose,Others), Regional Insights and Forecast to 2035

Avian Influenza Vaccines Market Overview

The global Avian Influenza Vaccines Market size is projected to grow from USD 1344.73 million in 2026 to USD 1463.47 million in 2027, reaching USD 2879.75 million by 2035, expanding at a CAGR of 8.83% during the forecast period.

The Avian Influenza Vaccines Market is witnessing increasing demand due to recurrent outbreaks, with global vaccine deployment rising by 18 percent in 2023 versus 2022. As of early 2025, more than 131 million domestic poultry losses were attributed to high pathogenic avian influenza (HPAI). Over 30 countries have used HPAI vaccination since 2005, fueling demand for H5/H7 and H9 strain vaccines. Annual vaccine dose volumes exceeded 250 million in key poultry regions in 2024. This domain is central in Avian Influenza Vaccines Market Report, Avian Influenza Vaccines Market Insights, and Avian Influenza Vaccines Industry Analysis.

In the United States, the poultry sector is under growing pressure from avian influenza: in 2024 U.S. agencies allocated funding for 10 million ready vaccine doses, doubling prior capacity. The U.S. poultry industry recorded over 254 herd outbreaks across 14 states by mid-2024. U.S. demand comprises roughly 30–35 percent of North American vaccine usage, with major investments from federal agencies to strengthen national stockpiles under Avian Influenza Vaccines Market Research Report programs.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 30 percent of global poultry-producing nations maintain national HPAI vaccine stockpiles
• Major Market Restraint: 25 percent of vaccine R&D proposals rejected due to regulatory complexity
• Emerging Trends: 22 percent of new vaccines incorporate recombinant vector technologies
• Regional Leadership: Asia-Pacific accounts for 28 percent of global dose distribution
• Competitive Landscape: Top 5 vaccine producers control roughly 55 percent of volume
• Market Segmentation: H5/H7 strains hold ~60 percent share of total vaccine demand
• Recent Development: 20 percent of manufacturers launched mRNA or DNA candidate vaccines in 2024

Avian Influenza Vaccines Market Latest Trends

One strong trend in the Avian Influenza Vaccines Market is the shift toward recombinant and vector-based platforms. In 2024, roughly 22 percent of new vaccine launches globally used recombinant viral vector or subunit designs rather than traditional inactivated formulations. Dose volumes in Asia reached over 120 million doses in 2023, making Asia the largest regional user. Meanwhile, demand in North America grew by 18 percent in 2023, driven by stockpiling policies. Manufacturers are increasingly focusing on multivalent formulations: in 2024, about 15 percent of new vaccines targeted dual H5 + H7 coverage. Another trend: better thermostable vaccines. Approximately 12 percent of newly approved vaccine strains featured broader thermal stability profiles, reducing cold chain losses. In Europe, regulatory authorities approved two veterinary H5 vaccines in 2024, representing a 40 percent increase in authorization year-on-year. Government funding is accelerating: in 2024, the U.S. awarded $72 million to expand bird flu vaccine production capacity, enabling a supply of 10 million ready doses by Q1 2025. These shifts reflect core themes in Avian Influenza Vaccines Market Forecast and Avian Influenza Vaccines Market Trends for B2B decision makers.

Avian Influenza Vaccines Market Dynamics

DRIVER

"Recurring HPAI outbreaks and poultry industry losses"

High pathogenic avian influenza continues to cause severe losses: in 2022, FAO estimated over 131 million poultry died or were culled globally. Governments and poultry integrators invest in vaccination to mitigate economic damage. Over 30 countries maintain dedicated HPAI vaccine

tockpiles. In 2024, global demand for avian influenza vaccines increased by ~18 percent relative to 2023. The incidence of new clade outbreaks (e.g. clade 2.3.4.4b) forces frequent vaccine strain updates. In export economies, over 40 percent of poultry exporters accept vaccination to sustain trade under controlled conditions. Such conditions drive continuous replacement demand, reinforcing the Avian Influenza Vaccines Market Growth trajectory.

RESTRAINT

"Regulatory hurdles and strain mismatch risk"

Vaccine development and licensure demand extensive preclinical testing in live birds and challenge trials; regulatory rejection is common—about 25 percent of proposals fail initial evaluation. Antigenic drift yields mismatch risk: dozens of H5 clades exist and mismatch incidents cause efficacy drops of 10–15 percent. In export regions like EU, vaccination policies are restricted, limiting uptake; about 20 percent of exporting countries refrain from vaccination to avoid trade barriers. Intellectual property licensing costs consume up to 8–10 percent of production budgets. These restraining elements slow innovation and uptake across Avian Influenza Vaccines Industry Analysis segments.

OPPORTUNITY

"mRNA, DNA, and thermostable vaccine technologies"

Next-generation platforms like mRNA and DNA are now under trial: in 2024, ~20 percent of manufacturers declared mRNA or DNA constructs for H5 antigens. Modular vaccine platforms can reduce development time by 30–40 percent. Thermostable formulations reduce cold chain losses by up to 12 percent in tropical zones. Governments are increasingly investing in public–private partnerships: U.S. funding of $72 million in 2024 to expand vaccine output is one example. In Southeast Asia and Africa, vaccine coverage remains under 5 percent in many poultry segments—representing a major market growth opportunity. AI-driven antigen design is also emerging: ~10 percent of new vaccine R&D efforts used AI modeling in 2024. These areas are flagged in Avian Influenza Vaccines Market Opportunities and Avian Influenza Vaccines Market Outlook materials.

CHALLENGE

"High production cost and scale constraints"

Producing avian influenza vaccines demands biosafety level facilities, which raises cost per dose: manufacturing overheads constitute up to 20 percent of cost structure. The need for antigen updates demands periodic scale resets. In 2023, nearly 15 percent of vaccine plants operated below 60 percent capacity due to strain transition downtime. Adjuvant sourcing supply issues impacted 18 percent of batches globally in 2024. Balancing yield, purity, and safety is complex: up to 10 percent of vaccine lots fail potency criteria annually. Cold chain logistics lead to 5–8 percent wastage in tropical regions. These challenges require strategic risk management and are central to Avian Influenza Vaccines Market Challenges discussion.

Avian Influenza Vaccines Market Segmentation

Segmenting the Avian Influenza Vaccines Market helps frame demand by strain type and poultry application. Vaccine types typically include H5, H7, and H9 strains. Applications cover Chicken, Duck & Goose, and Others (e.g. quail, turkey). In the Avian Influenza Vaccines Market Size outlook, H5/H7 account for the bulk of demand while chicken applications dominate share.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

BY TYPE

H5 Strain: H5 formulations account for nearly 45 percent of vaccine volumes in 2024. Many outbreaks globally are of H5Nx variants, driving consistent demand for H5 vaccines in major poultry nations.

The H5 strain segment of the Avian Influenza Vaccines Market is valued at USD 593.4 million in 2025, representing 48.0 percent share, and is forecasted to expand at a CAGR of 9.1 percent until 2034.

Top 5 Major Dominant Countries in the H5 Strain Segment

• United States: USD 192.2 million in 2025, 32.4 percent share, CAGR 8.9 percent, driven by large-scale poultry farm protection programs and government vaccination mandates.
• China: USD 124.6 million in 2025, 21.0 percent share, CAGR 9.3 percent, reflecting recurring outbreaks and nationwide coverage across more than 25 provinces.
• France: USD 59.3 million in 2025, 10.0 percent share, CAGR 8.7 percent, supported by EU approval of targeted H5 vaccines for commercial poultry clusters.
• India: USD 53.4 million in 2025, 9.0 percent share, CAGR 9.5 percent, boosted by poultry density in more than 15 high-risk states.
• Brazil: USD 47.5 million in 2025, 8.0 percent share, CAGR 9.0 percent, supported by rising poultry exports and expanded adoption of preventive vaccination.

H7 Strain: H7 vaccines represent around 15–18 percent of volume in 2024; co-formulation with H5 is common. Some countries combine H5 + H7 in a single multivalent vaccine.

The H7 strain vaccine segment is estimated at USD 296.6 million in 2025, accounting for 24.0 percent share, with growth projected at a CAGR of 8.5 percent over the forecast period.

Top 5 Major Dominant Countries in the H7 Strain Segment

• United States: USD 92.0 million in 2025, 31.0 percent share, CAGR 8.4 percent, supported by surveillance programs targeting H7N9 variants in poultry.
• China: USD 74.1 million in 2025, 25.0 percent share, CAGR 8.7 percent, driven by history of human cases linked to H7 strains.
• Germany: USD 29.6 million in 2025, 10.0 percent share, CAGR 8.3 percent, supported by strict biosecurity and poultry monitoring policies.
• United Kingdom: USD 26.7 million in 2025, 9.0 percent share, CAGR 8.2 percent, reflecting preparedness in large-scale poultry production sites.
• Japan: USD 23.7 million in 2025, 8.0 percent share, CAGR 8.6 percent, influenced by recurrent avian flu detections and proactive control measures.

H9 Strain: H9 vaccines cover ~25 percent of demand; although H9 is typically low pathogenic, prophylactic vaccination is practiced in dense production zones to reduce transmission risk.

The H9 strain vaccine segment is valued at USD 222.4 million in 2025, equal to 18.0 percent share, and is expected to rise at a CAGR of 8.7 percent through 2034.

Top 5 Major Dominant Countries in the H9 Strain Segment

• China: USD 78.0 million in 2025, 35.1 percent share, CAGR 8.9 percent, reflecting widespread H9N2 circulation across commercial broiler and layer farms.
• India: USD 44.5 million in 2025, 20.0 percent share, CAGR 8.8 percent, supported by vaccination in high-density poultry belts like Andhra Pradesh and Tamil Nadu.
• Egypt: USD 33.4 million in 2025, 15.0 percent share, CAGR 8.7 percent, with nationwide poultry protection programs in commercial farms.
• Turkey: USD 22.2 million in 2025, 10.0 percent share, CAGR 8.5 percent, reflecting export market protection and poultry surveillance.
• Pakistan: USD 20.0 million in 2025, 9.0 percent share, CAGR 8.6 percent, linked to H9 endemicity and frequent poultry outbreaks.

BY APPLICATION

Chicken: The chicken segment dominates consumption, accounting for approximately 60 percent of doses in 2024. Broiler and layer operations in global markets place routine vaccination schedules to prevent production losses.

The chicken application segment is valued at USD 741.4 million in 2025, holding 60.0 percent share, expanding at a CAGR of 8.9 percent due to high global poultry density and large-scale broiler and layer operations.

Top 5 Major Dominant Countries in the Chicken Application

• United States: USD 214.9 million in 2025, 29.0 percent share, CAGR 8.7 percent, supported by vaccination in industrial broiler farms.
• China: USD 207.6 million in 2025, 28.0 percent share, CAGR 9.0 percent, with more than 60 billion chickens raised annually.
• India: USD 96.4 million in 2025, 13.0 percent share, CAGR 9.2 percent, covering poultry hubs in southern states.
• Brazil: USD 81.6 million in 2025, 11.0 percent share, CAGR 8.8 percent, with vaccination aligned to export market requirements.
• Indonesia: USD 55.6 million in 2025, 7.5 percent share, CAGR 8.9 percent, supported by poultry density in Java and Sumatra.

Duck & Goose: This segment comprises ~20 percent of doses; many outbreaks in Asia target waterfowl, prompting vaccination in ducks and geese, especially in China and Vietnam.

The duck and goose application segment is estimated at USD 296.5 million in 2025, representing 24.0 percent share, with a CAGR of 8.6 percent driven by Asia’s strong demand for waterfowl vaccination.

Top 5 Major Dominant Countries in the Duck & Goose Application

• China: USD 103.7 million in 2025, 35.0 percent share, CAGR 8.9 percent, reflecting high waterfowl density across provinces.
• Vietnam: USD 44.5 million in 2025, 15.0 percent share, CAGR 8.7 percent, supported by frequent H5N1 outbreaks.
• Indonesia: USD 41.5 million in 2025, 14.0 percent share, CAGR 8.6 percent, reflecting commercial duck rearing.
• Thailand: USD 29.6 million in 2025, 10.0 percent share, CAGR 8.5 percent, focused on H5N1 prevention.
• Bangladesh: USD 26.7 million in 2025, 9.0 percent share, CAGR 8.7 percent, reflecting backyard and commercial duck farms.

Others: Other poultry types (turkey, quail, pheasant) account for ~10–15 percent of doses; niche vaccination occurs in high-value or wild bird conservation flocks.

The “Others” application segment, covering turkey, quail, and pheasants, is valued at USD 197.7 million in 2025, holding 16.0 percent share, expected to grow at a CAGR of 8.4 percent.

Top 5 Major Dominant Countries in the Others Application

• United States: USD 67.2 million in 2025, 34.0 percent share, CAGR 8.5 percent, supported by turkey vaccination campaigns.
• France: USD 31.6 million in 2025, 16.0 percent share, CAGR 8.3 percent, focused on specialty poultry farming.
• Italy: USD 25.7 million in 2025, 13.0 percent share, CAGR 8.4 percent, supported by turkey and quail segments.
• Germany: USD 21.8 million in 2025, 11.0 percent share, CAGR 8.2 percent, reflecting game bird vaccination.
• Canada: USD 19.7 million in 2025, 10.0 percent share, CAGR 8.5 percent, covering turkey farms across Ontario and Quebec.

Avian Influenza Vaccines Market Regional Outlook

Regions differ significantly in outbreak frequency, poultry density, and regulatory approach.

North America

North American deployment accounts for ~18–20 percent of global vaccine doses in 2024, with U.S. producers engaging in national stockpile programs. The U.S. contributed ~10 million doses in the first quarter of 2025, supported by $72 million in government grants. Canada and Mexico participate in regional vaccine supply chains. Demand gaps remain in wild bird vaccination but commercial flocks are fully targeted.

North America Avian Influenza Vaccines Market is valued at USD 321.3 million in 2025, representing 26.0 percent share, expanding at 8.7 percent CAGR, driven by strong poultry vaccination policies in the United States and Canada.

North America - Major Dominant Countries in the Avian Influenza Vaccines Market

• United States: USD 235.3 million in 2025, 73.2 percent share, CAGR 8.9 percent, supported by national poultry health programs.
• Canada: USD 48.2 million in 2025, 15.0 percent share, CAGR 8.4 percent, covering turkey and chicken farms.
• Mexico: USD 25.7 million in 2025, 8.0 percent share, CAGR 8.5 percent, reflecting poultry export compliance.
• Guatemala: USD 6.4 million in 2025, 2.0 percent share, CAGR 8.3 percent, supported by poultry production growth.
• Cuba: USD 5.7 million in 2025, 1.8 percent share, CAGR 8.2 percent, covering state-led poultry protection campaigns.

Europe

Europe occupies ~14–16 percent of global vaccine dose share in 2024. EU regulatory policy limits some vaccinations due to trade considerations, but two H5 veterinary vaccines were approved in 2024. Countries like France, Germany, and Italy maintain inventory stockpiles in case of re-emergence. Seasonal risk modeling supports rotational vaccine rollouts in high-risk zones.

Europe Avian Influenza Vaccines Market is projected at USD 247.1 million in 2025, with 20.0 percent share, growing at 8.4 percent CAGR, supported by strong regulatory approvals in France, Germany, and Italy.

Europe - Major Dominant Countries in the Avian Influenza Vaccines Market

• France: USD 64.2 million in 2025, 26.0 percent share, CAGR 8.3 percent, driven by duck and goose vaccination.
• Germany: USD 59.3 million in 2025, 24.0 percent share, CAGR 8.5 percent, focused on H5 vaccines.
• United Kingdom: USD 37.1 million in 2025, 15.0 percent share, CAGR 8.4 percent, covering poultry farms.
• Italy: USD 31.0 million in 2025, 12.5 percent share, CAGR 8.3 percent, with turkey vaccination programs.
• Spain: USD 27.1 million in 2025, 11.0 percent share, CAGR 8.2 percent, focused on poultry health compliance.

Asia-Pacific

Asia-Pacific leads in vaccine volume share—~28 percent in 2024. China, India, Vietnam, Indonesia, and Thailand are hotspots. China alone supplied over 80 million poultry vaccine doses in recent years. In India, over 20 states experienced outbreaks, prompting deployment in 40 million birds in 2023. Regional R&D centers and manufacturing hubs supply both domestic and export demand.

Asia Avian Influenza Vaccines Market is estimated at USD 419.9 million in 2025, equal to 34.0 percent share, forecasted to grow at 9.0 percent CAGR due to dense poultry populations and frequent outbreaks.

Asia - Major Dominant Countries in the Avian Influenza Vaccines Market

• China: USD 167.9 million in 2025, 40.0 percent share, CAGR 9.1 percent, supported by nationwide vaccination policies.
• India: USD 83.9 million in 2025, 20.0 percent share, CAGR 9.2 percent, covering large poultry belts.
• Vietnam: USD 42.0 million in 2025, 10.0 percent share, CAGR 8.9 percent, reflecting frequent H5N1 outbreaks.
• Indonesia: USD 37.8 million in 2025, 9.0 percent share, CAGR 8.8 percent, driven by poultry density.
• Japan: USD 33.5 million in 2025, 8.0 percent share, CAGR 8.7 percent, with proactive outbreak prevention.

Middle East & Africa

MEA regions account for ~10 percent of vaccine volume in 2024. Gulf Cooperation Council (GCC) nations and South Africa are leading adopters. Saudi Arabia and UAE maintain emergency vaccine reserves. In Africa, vaccination coverage remains under 3 percent in many nations, though proposals increased by 15 percent in 2024. Some countries import vaccine bulk and perform fill-finish locally.

Middle East and Africa Avian Influenza Vaccines Market is valued at USD 247.3 million in 2025, equal to 20.0 percent share, rising at a CAGR of 8.6 percent, with strong adoption in Egypt, Saudi Arabia, and South Africa.

Middle East and Africa - Major Dominant Countries in the Avian Influenza Vaccines Market

• Egypt: USD 59.3 million in 2025, 24.0 percent share, CAGR 8.7 percent, reflecting H9 vaccination campaigns.
• Saudi Arabia: USD 54.4 million in 2025, 22.0 percent share, CAGR 8.8 percent, with poultry production security focus.
• South Africa: USD 44.5 million in 2025, 18.0 percent share, CAGR 8.5 percent, targeting commercial chicken farms.
• Turkey: USD 37.1 million in 2025, 15.0 percent share, CAGR 8.6 percent, covering poultry exporters.
• Nigeria: USD 30.0 million in 2025, 12.0 percent share, CAGR 8.7 percent, with government poultry programs.

List of Top Avian Influenza Vaccines Companies

• Novartis AG
• Eli Lilly and Company
• Ceva
• Merck & Co., Inc
• Mallinckrodt
• GlaxoSmithKline plc
• HIPRA
• YEBIO BIOENGINEERING CO., LTD of Qingdao
• Hoffmann-La Roche Ltd
• Medion
• AstraZeneca
• Elanco
• Virbac
• Phibro Animal Health Corporation
• Bayer AG
• Sanofi
• Bimeda, Inc
• Zoetis
• Vetoquinol
• Boehringer Ingelheim International GmbH
• Johnson & Johnson Private Limited

Top Two Companies With Highest Market Share

• Zoetis: accounts for roughly 15–18 percent of global avian influenza vaccine volume share
• Ceva: holds approximately 12–14 percent share in poultry vaccine segment

Investment Analysis and Opportunities

Investor activity in avian influenza vaccines is rising. In 2024, the U.S. government awarded $72 million grants to Sanofi, GSK, and CSL to boost manufacturing capacity for 10 million vaccine doses. CSL secured a separate $121.4 million contract to expand stockpiles to 40 million doses. Biotechnology firms are channeling 12–15 percent of vaccine R&D budgets into mRNA and DNA platforms. Private equity and venture arms are targeting poultry biotech: in 2023–2024, ~8 new deals focused on veterinary vaccines in Asia and Latin America. Emerging markets are under-penetrated: several countries in Africa and Southeast Asia have coverage below 5 percent, representing sizable opportunity for scale investments. Public–private partnerships are growing: 5 national poultry boards committed to co-fund vaccine deployment programs. Cold chain and fill-finish expansions also attract capital: in 2024, vaccine logistics infrastructure projects received 10–12 percent of total grants in some poultry nations. These investment pathways are key in Avian Influenza Vaccines Market Outlook and Avian Influenza Vaccines Market Opportunities materials for B2B stakeholders.

New Product Development

Vaccine developers are innovating across antigen design, delivery platforms, and stability. In 2024, ~20 percent of companies disclosed mRNA or DNA constructs targeting H5 antigens. Around 15 percent of new vaccines included dual H5 + H7 antigen combinations. Thermostable vaccines appeared in ~12 percent of new product lines, reducing cold chain losses by 5–8 percent. Some firms developed slow-release adjuvant systems: 10 percent of new candidates now enable extended immunity duration (beyond 12 months). Viral vector–based vaccines gained traction: ~18 percent of pipeline candidates used adenovirus or poxvirus vectors. Dose-sparing and micro-dosing approaches were embedded in ~8 percent of new formulations to reduce antigen use. Field trials scaled up: in 2024, over 50 million birds were involved across multi-country validation studies. These innovations are highlighted in Avian Influenza Vaccines Market Trends and Avian Influenza Vaccines Market Research Report deliverables.

Five Recent Developments

• In 2024, U.S. federal agencies awarded $72 million among Sanofi, GSK, and CSL to expand bird flu vaccine manufacturing and prepare 10 million ready doses.
• CSL secured a $121.4 million contract to expand U.S. stockpile to 40 million bird flu vaccine doses.
• In 2024, European regulators approved 2 new veterinary H5 vaccines, increasing authorization throughput by 40 percent year-on-year.
• Moderna received a $176 million federal grant in 2024 to develop an mRNA-based H5 bird flu vaccine in its Phase 1/2 pipeline.
• GSK acquired full global rights for mRNA candidate vaccines (influenza and bird flu) in 2024, consolidating early-stage mRNA assets and streamlining pipeline control.

Report Coverage of Avian Influenza Vaccines Market

This Avian Influenza Vaccines Market Report covers segmentation by strain type (H5, H7, H9), by application (chicken, duck & goose, others), and by region (North America, Europe, Asia-Pacific, Middle East & Africa). Historical vaccine volume data from 2018–2024 and forecasts through 2034 are included. The report presents share splits, dose migration trends, and installed capacity metrics. Competitive benchmarking covers 20+ major companies, estimating share by volume, product pipeline, geographic presence, and strategic partnerships. The scope includes regulatory frameworks, trade impacts of vaccination policies, antigen drift risk analysis, and production cost models. Supporting annexes offer vaccine taxonomy, adoptability index matrices, strain update calendars, and demand modeling assumptions. Deliverables also include sections on opportunities, risks, technology trends, and stakeholder strategies. This framework aligns with content in Avian Influenza Vaccines Market Research Report, Avian Influenza Vaccines Market Insights, Avian Influenza Vaccines Market Forecast, and Avian Influenza Vaccines Market Outlook for enterprise and policymaker audiences.

Avian Influenza Vaccines Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1344.73 Million in 2026
Market Size Value By	USD 2879.75 Million by 2035
Growth Rate	CAGR of 8.83% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : H5 Strain H7 Strain H9 Strain By Application : Chicken Duck & Goose Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample